Depresión perimenopáusicauna revisión

  1. Sesma Pardo, Eva
  2. Finkle, Joshua
  3. González Torres, Miguel Ángel
  4. Gaviria, Moisés
Revue:
Revista de la Asociación Española de Neuropsiquiatría

ISSN: 0211-5735

Année de publication: 2013

Volumen: 33

Número: 120

Pages: 681-691

Type: Article

DOI: 10.4321/S0211-57352013000400002 DIALNET GOOGLE SCHOLAR lock_openAccès ouvert editor

D'autres publications dans: Revista de la Asociación Española de Neuropsiquiatría

Objectifs de Développement Durable

Résumé

From adolescence, women have a 1.5 to 3 times higher risk than men of suffering from a depressive disorder. This risk increases in the transition period to menopause or perimenopause, when the depressive vulnerability becomes especially intense. Hormonal, psychological and sociocultural factors have been suggested to understand the etiopathogeny of these disorders. Treatment of depression in perimenopause is determined by clinical severity and includes antidepressants, psychotherapy, and sometimes, hormone replacement therapy with estrogens. Perimenopausal depression is an underdiagnosed and poorly treated problem, which generates a high level of suffering and deserves greater attention by clinicians and health systems.

Références bibliographiques

  • (1) Avis NE, Stellato R, Crawford S, Bromberger J, Ganz P, Cain V, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52(3):345- 56.
  • (2) Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997;45:19-30.
  • (3) Kessler RC. Epidemiology of women and depression. J Affect Disord 2003;74:5-13.
  • (4) Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, 7th edition. 2003, Elsevier.
  • (5) Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch-Jacquotte A (1998). “Prospective study of factors influencing the onset of natural menopause”. J Clin Epidemiol 51(12):1271– 76.
  • (6) Kaufman DL, Slone D, Rosenberg L, Miettinen OS, Shapiro S. Cigarette smoking and age of natural menopause. American Journal of Public Health 1980;70(4):420-22.
  • (7) Mosby’s Medical Dictionary, 8th edition. 2009, Elsevier.
  • (8) Blake J: Menopause: evidence-based practice. Best Pract Res Clin Obstet Gynaecol 2006; 20:799–839.
  • (9) Freeman EW, Samuel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychyatry 2006;63:375- 82.
  • (10) Bosworth HB, Bastian LA, Kuchibhatla MN, Steffens DC, McBride CM, Skinner CS, et al. Depressive symptoms, menopausal status, and climacteric symptoms in women at midlife. Psychosom Med 2001;63:603-8.
  • (11) Gyllstrom ME, Schereiner PJ, Harlow BL. Perimenopause and depression: strength of association, causal mechanisms and treatment recommendations. Best Pract Res Clin Obstet Gynaecol 2007;21:275-92.
  • (12) Burger HG, Dudley EC, Hopper JL et al. Prospectively measured levels of serum FSH, estradiol and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84:4025-30.
  • (13) Klein NA, Illingworth PJ, Groome NP et al. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 1996;81:2742-45.
  • (14) Santoro N. The menopause transition. Am J Med 2005;118(12 Suppl):8S-13S.
  • (15) Rannevik G, Jeppsson S, JohnellOet al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995;21:103-13.
  • (16) Stearns V, Ullmer L, Lopez JF et al. Hot flushes. Lancet 2002 Dec;360: 1851-61.
  • (17) Freedman RR. Physiology of hot flushes. Am J Human Biol 2001;13:453-64.
  • (18) Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hotflushes. Am J Obstet Gynecol 1999;181:66-70.
  • (19) Dzaja A, Arber S, Hislop J et al. Women’s sleep in health and disease. J Psychiatr Res 2005 Jan;39(1):55-76.
  • (20) Moe KE. Hot flushes and sleep in women. Sleep Med Rev 2004 Dec;8(6):487-97.
  • (21) Szoeke CE, Cicuttini F, Guthrie J et al. Self-reported arthritis and the menopause. Climacteric 2005 Mar;8(1):49-55.
  • (22) Dennerstein Lorraine, Lehert Philippe, Burger Henry et al. Sexuality. Am J Med 2005;118(12 Suppl):59S-63S.
  • (23) Leiblum Sandra R, Koochaki Patricia E, Rodenberg Cynthia A et al. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women’s International Study of Health and Sexuality (WISHeS). Menopause 2006;13(1):46-56.
  • (24) Kaufert PA, Gilbert P & Tate R. The Manitoba Project: a re-examination of the link between menopause and depression. Maturitas 1992;14:143-55.
  • (25) Woods NF, Mariella A, Mitchell ES. Patterns of depressed mood across the menopausal transition: approaches to studying patterns in longitudinal data. Acta Obstet Gynecol Scand 2002;81:623- 32.
  • (26) Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61(1):62–70.
  • (27) Daly RC, Danaceau MA, Rubinow DR, Schmidt PJ. Concordant restoration of ovarian function and mood in perimenopausal depression. Am J Psychiatry 2003;160:1842-46.
  • (28) Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2003;60(1):29-36.
  • (29) Avis NE, Crawford S, Stellato R, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001;4:243-49.
  • (30) Rannevik G, Jeppsson S, Johnell O. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995;21:103- 13.
  • (31) Avis NE, Brambilla D, McKinlay SM et al. A longitudinal analysis of the association between menopause and depression: results from the Massachusetts women’s health survey. Ann Epidemiol 1994;4:214-20.
  • (32) Avis NE, Kaufert PA, Lock M, McKinlay SM, Vass K. The evolution of menopausal symptoms. Baillieres Clin Endocrinol Metab 1993 Jan;7(1):17-32.
  • (33) Hershey DA, Henkens K, Van Dalen HP. Aging and financial planning for retirement: interdisciplinary influences viewed through a cross-cultural lens. Int J Aging Hum Dev 2010;70(1):1-38.
  • (34) Kobayashi KM, Funk L. Of the family tree: congruence on filial obligation between older parents and adult children in Japanese Canadian families. Can J Aging 2010 Mar;29(1):85-96.
  • (35) Takagi E, Silverstein M, Crimmins E. Intergenerational coresidence of older adults in Japan: conditions for cultural plasticity. J Gerontol B Psychol Sci Soc Sci 2007 Sep;62(5):330-39.
  • (36) Dennerstein L, Dudley E, Guthrie J. Empty nest or revolving door? A prospective study of women’s quality of life in midlife during the phase of children leaving and re-entering the home. Psychol Med 2002;32:545-50.
  • (37) Guthrie JR, Dennerstein L, Taffe JR. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women’s Midlife Health Project. Climacteric 2004 Dec;7(4):375- 89.
  • (38) Woods NF, Mariella A, Mitchell ES. Patterns of depressed mood across the menopausal transition: approaches to studying patterns in longitudinal data. Acta Obstet Gynecol Scand 2002;81:623- 32.
  • (39) Daly E, Gray A, Barlow D et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993 Oct 2;307:836-40.
  • (40) Larroy García C, Gómez-Calcerrada SG. Cognitive-behavioral intervention among women with slight menopausal symptoms: a pilot study. Span J Psychol 2011 May;14(1):344-55.
  • (41) Iglesias García C, Ocio León S, Ortigosa Digón JC, et al. Comparison of the effectiveness of venlafaxine in periand postmenopausal patients with major depressive disorder. Actas Esp Psiquiatr 2010 Nov-Dec;38(6):326-31.
  • (42) Ushiroyama T, Ikeda A, Ueki M. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition. J Med 2004;35(1-6):151- 62.
  • (43) Morrison MF, Kallan MJ, Ten Have Tet al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled. Biol Psychiatry 2004 Feb 15; 55(4):406-12.
  • (44) Resnick S, Maki P, Rapp S, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006, 91(5):1802-10.
  • (45) De Noaves Soares C, Almeida OP, Joffee H et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. Arch Gen Psychiatry 2001;58:529-34.
  • (46) Schmidt Peter J. Mood, depression, and reproductive hormones in the menopausal transition. Am J Med 2005 December 19; 118 (12 Suppl 2): 54-8.
  • (47) Writing Group for the Women’s Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321.
  • (48) The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
  • (49) Collins JA, Blake JM & Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005;11(6):545-60.
  • (50) Craig MC, Murphy DG. Estrogen therapy and Alzheimer’s dementia. Ann N Y Acad Sci 2010 Sep;1205:245-53.
La source de données: Dialnet